Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
NCT: NCT07408154 · RECRUITING
Brief Summary
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.
Frequently Asked Questions
What is Direct vs Standard SLT for Glaucoma: A Noninferiority Trial?
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial is a clinical trial registered under NCT07408154. Current status: RECRUITING.
What is the status of NCT07408154?
The current status of NCT07408154 (Direct vs Standard SLT for Glaucoma: A Noninferiority Trial) is: RECRUITING.
When did Direct vs Standard SLT for Glaucoma: A Noninferiority Trial start?
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial started on 2026-04-27.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.